CHAPEL HILL, N.C.--(BUSINESS WIRE)--June 12, 2003--POZEN Inc.
(NASDAQ:POZN) announced that it will host a webcast at 10:00 a.m.
Eastern Time on Thursday, June 12, 2003 to discuss the Company's
licensing agreement with GSK to develop and commercialize a novel
migraine treatment. John R. Plachetka, Pharm.D., POZEN's chairman,
president and chief executive officer, and Matthew E. Czajkowski,
chief financial officer, will host the presentation. The presentation
will be webcast live with slides and archived on POZEN's home page at
POZEN is a pharmaceutical company developing therapeutic
advancements in a cost effective manner. Since its inception, POZEN
has developed the largest and most advanced product pipeline in the
field of migraine. Product development efforts are focused on diseases
with unmet medical needs where POZEN can improve efficacy, safety,
and/or patient convenience. The company's common stock is traded on
The NASDAQ Stock Market under the symbol "POZN." For detailed company
information, see POZEN's website: www.pozen.com.
Chief Financial Officer
Director, Investor Relations